Group 1 - The core announcement is that Insilico Medicine (03696) has entered into an exclusive licensing and co-development agreement with Shenzhen Hengtai Biotechnology Co., Ltd. for the ISM8969 project, a novel oral NLRP3 inhibitor aimed at treating central nervous system diseases [1] - The collaboration aims to accelerate the global development of ISM8969, which has the ability to penetrate the blood-brain barrier [1] - Insilico Medicine will receive up to $66 million (approximately HKD 514.8 million) in upfront and milestone payments, including an initial payment of $10 million (approximately HKD 78 million) within 30 days of the agreement's effective date [1] Group 2 - ISM8969 is identified as a potential best-in-class NLRP3 inhibitor, discovered and optimized through Insilico Medicine's proprietary generative chemistry engine, Chemistry42 [2] - Preclinical studies have shown ISM8969 to exhibit excellent efficacy and safety, demonstrating significant anti-inflammatory activity across various disease models [2] - The compound has ideal blood-brain barrier penetration capabilities, which may provide potential benefits for treating neuroinflammatory-related diseases [2]

Core Viewpoint - 英矽智能 has entered into an exclusive licensing and co-development agreement with Shenzhen Hengtai Biotechnology Co., Ltd. for the ISM8969 project, aimed at accelerating the global development of a new oral NLRP3 inhibitor for central nervous system diseases [1] Group 1: Agreement Details - The agreement grants Shenzhen Hengtai the rights to research, develop, register, produce, and commercialize ISM8969 globally, with both parties holding 50% global rights to the project [1] - 英矽智能 is entitled to receive up to $66 million (approximately HKD 514.8 million) in upfront and milestone payments, including an expected upfront payment of $10 million (approximately HKD 78 million) within 30 days of the agreement's effective date [1] Group 2: Company Background - Shenzhen Hengtai Biotechnology Co., Ltd. was incubated by Shenzhen Pengfu Biomedical Industry Private Equity Investment Fund Partnership and Fosun Pharma, focusing on innovative biotechnology in the field of autoimmune diseases [1] - Established in August 2025, the company aims to introduce and develop innovative pipelines with "best-in-class" potential globally, providing breakthrough treatment solutions through efficient R&D and commercialization capabilities [1]